Changchun Genescience Pharmaceutical Co., Ltd.

This study tests a new drug called GenSci145 in people whose advanced solid tumors have a specific change in the PIK3CA gene. The trial has two parts: first, finding a safe dose, then seeing if the drug works alone or with other treatments. About 186 adults aged 18-75 with tumors…

This study tests a new drug called GenSci120 in 450 adults with moderate-to-severe rheumatoid arthritis who haven't improved with standard treatments. Participants receive either GenSci120, an existing drug (adalimumab), or a placebo for 14 weeks, followed by an extension period.…

This early-stage trial tests a new drug called GenSci134 in healthy adults and patients with adult growth hormone deficiency. The main goal is to check safety and how well the body tolerates it. Researchers will give single or multiple doses and watch for side effects. It is a sm…

This early-stage study tests a new medicine called GenSci136 in 48 healthy adults in China. The goal is to check if a single shot is safe and how the body processes it. This is a first step toward possibly treating autoimmune diseases, where the immune system attacks the body.

This early-stage trial tests a single injection of a new drug called GenSci098 in 24 adults with Graves' disease, a condition where the thyroid is overactive. The main goal is to check safety and side effects over about 5 months. Researchers will also measure how the drug moves t…

This study tests a new weekly growth hormone injection (PEG-rhGH) against the standard daily shot in 72 short children born small for gestational age. The children, aged 3 and up with no puberty signs, will receive either a low or high weekly dose or a daily dose for 26 weeks. Th…

This early-stage trial is testing a new drug called GenSci098 in 76 adults with active thyroid eye disease (TED). The main goal is to check the drug's safety and how the body processes it at different doses. Participants will receive either the drug or a placebo as a shot under t…

This early-stage trial tests a new drug called GenSci143 in 180 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can control tumor growth. Participants receive the drug by in…

This study tests a new pill called GenSci128 in people whose advanced solid tumors have a specific change in the TP53 gene (Y220C). The main goals are to check the pill's safety, find the best dose, and see if it can shrink tumors. About 82 participants will take the pill by mout…

This early-stage study tests a new drug called GenSci139 in about 280 people with advanced solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is currently recruiting participants.

This early-stage study tests a new drug called GenSci140 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 170 adults in China will take part,…

This study tests whether cabergoline works better than bromocriptine for women with high prolactin levels. About 382 women aged 18-45 will take one of the two drugs for 14 weeks. The main goal is to see whose prolactin levels return to normal, along with checking ovulation, breas…

This study looks at whether nanocrystalline megestrol acetate can improve appetite and weight in people with cancer cachexia—a condition where patients lose weight and muscle. About 495 adults with cancer will take the drug daily for up to 12 weeks. Researchers will check appetit…

This phase 3 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced non-small cell lung cancer maintain their appetite and avoid significant weight loss while undergoing chemoradiotherapy. About 134 participants will receive either the d…

This study tests whether smoking changes how the body processes a single dose of GS1-144 tablets. It involves 24 healthy Chinese women aged 40-65 who are postmenopausal. Researchers will measure drug levels in the blood to see if smoking affects the drug's breakdown. The goal is …

This early-phase trial is testing a single injection of GenSci161 in 44 healthy adults aged 18 to 45. The main goal is to check for side effects and how the drug moves through the body. No one expects a medical benefit—this is purely about safety and dosing information.

This early-stage study tests the safety of a new drug called GS3-007a in 32 healthy Chinese adults aged 18-45. Participants receive either the drug or a placebo, and researchers monitor side effects and how the drug moves through the body. The study also checks if food affects dr…